newsfilter
← Earnings
Earnings Releases·

Avalo Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $18.9 million in Q3 2026 from $30.6 million in Q3 2025, driven by a $210 million gain on derivative liability fair value changes and higher interest income, despite R&D and G&A expenses rising to $15.0 million and $8.4 million respectively.
  • Strong balance sheet with $462.8 million in cash, cash equivalents, and investments as of September 30, 2026, sufficient to fund operations through 2029, supported by a total stockholders' equity increase to $436.5 million.
  • Strategic progress includes FDA feedback expected on abdakibart's development plan by year-end 2026, with registrational Phase 3 initiation for HS planned for H1 2027 and an IND submission for AVTX-010 anticipated in the same period.
  • R&D expense growth reflects increased CMC costs for AVTX-010 and abdakibart manufacturing, partially offset by reduced clinical expenses following the positive Phase 2 LOTUS trial data readout in May 2026.
Company
AVALO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology